Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.
Nerve Repair Pionee | Explore AxoGen's innovative solutions in peripheral nerve injury, driving its market leadership and expanding its addressable market to $5.6 billion |
Financial Trajectory | Delve into AxoGen's robust revenue growth and long-term projections, including a 15-20% CAGR and anticipated profitability by 2025 |
Regulatory Catalyst | Learn about the potential game-changing BLA approval for Avance Nerve Graft, expected in September 2025, which could grant 12+ years of market exclusivity |
Analyst Optimism | Discover why analysts set price targets ranging from $24 to $26, reflecting confidence in AxoGen's strategic initiatives and market expansion |
Metrics to compare | AXGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAXGNPeersSector | |
---|---|---|---|---|
P/E Ratio | −79.8x | −3.5x | −0.5x | |
PEG Ratio | −1.18 | −0.19 | 0.00 | |
Price/Book | 5.4x | 2.8x | 2.6x | |
Price / LTM Sales | 2.9x | 2.4x | 3.3x | |
Upside (Analyst Target) | 91.2% | 66.3% | 43.5% | |
Fair Value Upside | Unlock | 3.4% | 6.3% | Unlock |